Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythaemia.

G Tobelem

    Bailliere'S Clinical Haematology
    |July 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Essential thrombocythaemia (ET) is a rare blood disorder causing high platelet counts. Understanding its platelet defects is key to managing complications and treatment toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Did animal offer relevant model for Bevacizumab testing?

    British journal of cancer·2008
    Same author

    [Physiologic and neoplastic angiogenesis].

    Journal de chirurgie·2008
    Same author

    Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha.

    Journal of thrombosis and haemostasis : JTH·2003
    Same author

    Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin.

    Thrombosis research·2001
    Same author

    [Behcet's disease manifested as a intracranial aneurysm].

    La Revue de medecine interne·2001
    Same author

    Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis.

    Thrombosis and haemostasis·2000
    Same journal

    Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

    Bailliere's clinical haematology·2000
    Same journal

    Pharmacological therapy.

    Bailliere's clinical haematology·2000
    Same journal

    Prenatal diagnosis and screening of the haemoglobinopathies.

    Bailliere's clinical haematology·2000
    Same journal

    Sickle cell disease: clinical management.

    Bailliere's clinical haematology·2000
    Same journal

    Pathophysiology of sickle cell disease.

    Bailliere's clinical haematology·2000
    Same journal

    Thalassaemia: clinical management.

    Bailliere's clinical haematology·2000
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Internal Medicine

    Background:

    • Essential thrombocythaemia (ET) is a rare myeloproliferative disorder marked by elevated platelet counts.
    • Diagnosis typically relies on criteria from the Polycythemia Vera Study Group, excluding platelet count thresholds.
    • The condition commonly affects individuals around 60 years old, presenting with microcirculatory disturbances and neurological symptoms.

    Purpose of the Study:

    • To review the diagnostic criteria, clinical manifestations, and complications of Essential thrombocythaemia.
    • To explore the underlying pathogenesis, including megakaryocyte progenitor cell expansion and platelet abnormalities.
    • To discuss current treatment strategies and the challenges in balancing efficacy with drug toxicity.

    Main Methods:

    Related Experiment Videos

  • Review of diagnostic criteria and clinical presentation of ET.
  • Analysis of platelet function tests, including aggregation studies.
  • Examination of reported treatment outcomes and pathogenetic mechanisms.

    • Main Results:

    • Microcirculatory and neurological symptoms are frequent at diagnosis; thrombotic and hemorrhagic complications occur.
    • Platelet aggregation abnormalities are common, with nil adrenaline aggregation being highly discriminative.
    • Intrinsic defects in megakaryocytes likely cause platelet abnormalities, though direct links to bleeding/thrombosis are unclear.

    Conclusions:

    • ET management requires balancing complication prevention with treatment-related toxicity.
    • Recombinant alpha-interferon is a potential therapeutic option under investigation.
    • Further research is needed to clarify the causal relationship between platelet defects and clinical outcomes in ET.